Trial Profile
A Phase I/II Double-Blind, Randomised, Placebo-Controlled, Adaptive Design Study of the Safety, Tolerability, Immunogenicity and Efficacy of ACI-24 in Patients with Mild to Moderate Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 22 Nov 2018
Price :
$35
*
At a glance
- Drugs ACI 24 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; First in man; Pharmacodynamics; Therapeutic Use
- Sponsors AC Immune
- 16 Nov 2018 Status changed from recruiting to completed.
- 26 Sep 2018 This trial was completed in Finland, according to European Clinical Trials Database.
- 19 Jan 2018 This study has been completed in Denmark as per European Clinical Trials Database.